Eledon Pharmaceuticals, Inc. announced on November 6, 2025, that its estimated cash, cash equivalents, and short-term investments as of September 30, 2025, were approximately $93.4 million, pending final accounting procedures. Additionally, the company reported updated results from its Phase 2 BESTOW trial aimed at preventing organ rejection in kidney transplant patients.